Given what we are trying to do, that is, give the pharmaceutical companies an opportunity to have their say—I think we can simply ask for senior executives and let the companies decide who to send. Obviously, if they send their legal department heads, we will know that we are dealing with a legal issue, and we can debate what's more important: the constitutional conditions of transparency and democracy or purchase agreements. It would be quite the debate, I'm sure.
As far as scheduling goes, I just want to say that my preference is to hold the meeting as soon as possible, ideally next week. However, if the committee wishes to schedule the meeting on Thursday, March 23, I will go along with that.